NOV 20, 2019 12:27 PM PST

New diagnostic technology seeks out cancer DNA in blood

WRITTEN BY: Tara Fernandez

For many cancers, early detection has a tremendous impact on patient outcomes. Yet, sadly, many of the most common malignancies, like those of the stomach, colon, liver, breast, and lung, still lack robust diagnostic tests.

In a recent TEDx Talk, Dr. Anne Marie Lennon presented exciting clinical findings from testing a new molecular diagnostic platform developed by herself and colleagues at Johns Hopkins University. This cutting edge technology, called CancerSEEK, has the potential of being a game-changer for catching cancer earlier, by accurately detecting trace amounts of cancer DNA with a simple blood test.

Lennon, a medical doctor and Associate Professor of Medicine at Johns Hopkins, is an expert in early cancer detection and prevention, having authored over 100 peer-reviewed papers on the topic.

The problem with spotting cancer molecules circulating in the bloodstream is that they are present only in extremely minute quantities. As Lennon describes it: it’s like finding a needle in a haystack. For every 10,000 DNA fragments in a cancer patient’s blood sample, only between 1 and 5 of those are mutated sequences, indicative of the presence of disease.

The first iteration of the platform, known as Safe-SeqS, used a DNA barcode attached to a single mutant DNA template as a means to gauge the system’s sensitivity. Sequencing DNA in blood draws from cancer patients and healthy controls revealed that Safe-SeqS could positively identify around 30 percent of those taken from pancreatic cancer sufferers.

This was in itself a major milestone, considering no early detection strategies for pancreatic cancer currently exist and consequently, only 7 percent of diagnosed patients survive the disease.

In a bid to improve Safe-SeqS’ diagnostic capabilities, the researchers took a two-fold approach towards designing CancerSEEK. This new platform combed liquid biopsies, picking up both tumor DNA as well as other known molecular markers associated with a variety of common cancers. This system doubled its hit rate with a median of 70 percent of cancer samples correctly identified, with no false-positive hits for healthy controls.

Among CancerSEEK’s most impressive scores was a 98 percent positive discovery of samples from patients with liver and ovarian cancers.

On a positive note, CancerSEEK looks to have a clear path to becoming a routine part of medical care, with the inventors already hauling in $110 million in investment dollars to commercialize the technology.

Sources: TEDx Talks, Johns Hopkins University

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 16, 2020
Microbiology
Newly Discovered Gut Enzyme Could Function as Disease Biomarker
AUG 16, 2020
Newly Discovered Gut Enzyme Could Function as Disease Biomarker
Bacteria in the gut have a powerful influence on our health, in part because all of those microbes have genes of their o ...
SEP 03, 2020
Clinical & Molecular DX
Tiny Diagnostic Robot Tank Explores the Colon
SEP 03, 2020
Tiny Diagnostic Robot Tank Explores the Colon
The colon, also known as the large intestine, is where the final stages of digestion happen. Here, water, salts, and rem ...
SEP 21, 2020
Cancer
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
SEP 21, 2020
The Protein ETV1 May Act as a Biomarker for Gastrointestinal Cancer
Cancer is an incredibly diverse disease. It has many types and even sub-types, with a vast range of characteristics. Som ...
SEP 28, 2020
Cancer
A New Transcriptomics Program in the Works Glioma Diagnosis
SEP 28, 2020
A New Transcriptomics Program in the Works Glioma Diagnosis
The future of medicine is “personalized healthcare.” However, testing remains a critical hurdle researcher&r ...
OCT 08, 2020
Cardiology
Omega-3 Enriched Chicken as a Fish Alternative for Omega-3 Fatty Acids
OCT 08, 2020
Omega-3 Enriched Chicken as a Fish Alternative for Omega-3 Fatty Acids
We have all seen those articles telling us to get more omega-3 fatty acids in our diet. Many studies point to these spec ...
OCT 22, 2020
Cardiology
Using Liposomes to Deliver Repair Packages to the Heart
OCT 22, 2020
Using Liposomes to Deliver Repair Packages to the Heart
The secret to any successful drug is not just its ability to treat a disease but its ability to target the disease exclu ...
Loading Comments...